Post‐ versus presynaptic plasticity in L‐DOPA‐induced dyskinesia
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
L‐3,4‐dihydroxyphenylalanine (L‐DOPA) remains the most efficacious drug for the treatment of Parkinson's disease (PD), but causes adverse effects that limit its utility. L‐DOPA‐induced dyskinesia (abnormal involuntary movements) is a significant clinical problem that attracts growing scientific interest. Current notions attribute the development of dyskinesia to two main factors, viz. the loss of nigrostriatal dopamine (DA) projections and the maladaptive changes produced by L‐DOPA at sites postsynaptic to the nigrostriatal neuron. Basic research in the past 15 years has placed a lot of emphasis on the postsynaptic plasticity associated with dyskinesia, but recent experimental work shows that also some presynaptic factors, involving the regulation of L‐DOPA/DA release and metabolism in the brain, may show plasticity during treatment. This review summarizes significant studies of L‐DOPA‐induced dyskinesia in patients and animal models, and outlines directions for future experiments addressing mechanisms of presynaptic plasticity. These investigations may uncover clues to the varying susceptibility to L‐DOPA‐induced dyskinesia among PD patients, paving the way for tailor‐made treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689 · cited 2×
“Although it has become increasingly clear that PD is a multisystem synucleinopathy (Braak et al. 2004), severe degeneration of nigrostriatal dopamine (DA) neurons”
BackgroundRascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Hayashi, Y., Shi, S.-H., Esteban, J. A., Piccini, A., Poncer, J.-C., & Malinow, R. (2000) · Science · doi:10.1126/science.287.5461.2262 · Cited by 1,524 · cited 7×
“Moreover, the larger increase in extracellular DA levels in dyskinetic rats was not matched by a proportional increase in the production of the Journal Compilation 2006 International Society for Neurochemistry, J. Neurochem.”
BackgroundInfluentialDopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens
Nicola, S. M., Surmeier, D. J., & Malenka, R. C. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.185 · Cited by 931
A cellular mechanism of reward-related learning
Reynolds, J. N. J., Hyland, B. I., & Wickens, J. R. (2001) · Nature · doi:10.1038/35092560 · Cited by 879 · cited 1×
“This physical proximity allows for a tight functional interaction between glutamatergic and dopaminergic inputs in modulating the plasticity of corticostriatal transmission (Graybiel 1995; Reynolds et al. 2001).”
BackgroundLoss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia
Picconi, B., Centonze, D., Håkansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M. A., & Calabresi, P. (2003) · Nature Neuroscience · doi:10.1038/nn1040 · Cited by 821 · cited 6×
“Treatment with L-DOPA restores corticostriatal LTP, but animals that develop dyskinesia during the treatment show a synaptic abnormality consisting in a loss of LTP-reversal upon lowfrequency stimulation of cortical afferents (Picconi et al. 2003).”
BackgroundInfluentialSelf-citationThomas, M. J., Beurrier, C., Bonci, A., & Malenka, R. C. (2001) · Nature Neuroscience · doi:10.1038/nn757 · Cited by 629 · cited 2×
“Moreover, the larger increase in extracellular DA levels in dyskinetic rats was not matched by a proportional increase in the production of the Journal Compilation 2006 International Society for Neurochemistry, J. Neurochem.”
BackgroundLee, F. J. S., Xue, S., Pei, L., Vukusic, B., Chéry, N., Wang, Y., Wang, Y. T., Niznik, H. B., Yu, X.-M., & Liu, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00962-5 · Cited by 542
It could be habit forming: drugs of abuse and striatal synaptic plasticity
Gerdeman, G. L., Partridge, J. G., Lupica, C. R., & Lovinger, D. M. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00065-1 · Cited by 480 · cited 3×
“Accurate pharmacodynamic analyses in larger groups of patients revealed, however, that the presynaptic storage hypothesis could not alone account for the profound differences in motor response between early and advanced PD (Nutt et al. 1992; Nutt and Holford 1996; Nutt et al. 1997).”
Background
Cited by
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
Calabresi, P., Filippo, M. D., Ghiglieri, V., Tambasco, N., & Picconi, B. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70218-0 · Cited by 388
Fieblinger, T., Graves, S. M., Sebel, L. E., Alcacer, C., Plotkin, J. L., Gertler, T. S., Chan, C. S., Heiman, M., Greengard, P., Cenci, M. A., et al. (2014) · Nature Communications · doi:10.1038/ncomms6316 · Cited by 295
Self-citationCenci, M. A., & Lundblad, M. (2007) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0925s41 · Cited by 266
Self-citationDopamine dysregulation of movement control in l-DOPA-induced dyskinesia
Cenci, M. A. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.005 · Cited by 265
Self-citationLindgren, H. S., Andersson, D. R., Lagerkvist, S., Nissbrandt, H., & Cenci, M. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06556.x · Cited by 263
Self-citationMaladaptive plasticity of serotonin axon terminals in levodopa‐induced dyskinesia
Rylander, D., Parent, M., O'Sullivan, S. S., Dovero, S., Lees, A. J., Bezard, E., Descarries, L., & Cenci, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.22097 · Cited by 262
Self-citationMaladaptive striatal plasticity in l-DOPA-induced dyskinesia
Cenci, M. A., & Konradi, C. (2010) · Progress in Brain Research · doi:10.1016/s0079-6123(10)83011-0 · Cited by 216
“…Angela.Cenci_Nilsson@med.lu.se compromised by the loss of nigrostriatal DA DOI: 10.1016/S0079-6123(10)83011-0 209 neurons, because other cell systems in the brain are endowed with the enzyme that converts L-DOPA to DA [aromatic amino acid decarboxylase; reviewed in Cenci and Lundblad (2006)].”
BackgroundInfluentialSelf-citationDopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia
Jarraya, B., Boulet, S., Scott Ralph, G., Jan, C., Bonvento, G., Azzouz, M., Miskin, J. E., Shin, M., Delzescaux, T., Drouot, X., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000130 · Cited by 186
Sgambato-Faure, V., & Cenci, M. A. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.10.005 · Cited by 169
Self-citationNicotine and Parkinson's disease: implications for therapy
Quik, M., O'Leary, K., & Tanner, C. M. (2008) · Movement Disorders · doi:10.1002/mds.21900 · Cited by 154
Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys
Quik, M., Cox, H., Parameswaran, N., O'Leary, K., Langston, J. W., & Di Monte, D. (2007) · Annals of Neurology · doi:10.1002/ana.21203 · Cited by 133
Bordia, T., Campos, C., Huang, L., & Quik, M. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.140897 · Cited by 120
“Studies in 6-OHDA-lesioned rats show that the incidence of AIMs correlates with elevated striatal levels of L-DOPA, dopamine, and its metabolites, that is, L-DOPA-treated lesioned animals with higher striatal levels of these compounds develop AIMs, whereas those with lower levels do not (Carta et al., 2006; Cenci and…”
InfluentialChotibut, T., Davis, R. W., Arnold, J. C., Frenchek, Z., Gurwara, S., Bondada, V., Geddes, J. W., & Salvatore, M. F. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8598-0 · Cited by 86
Striatal glutamatergic hyperactivity in Parkinson's disease
Campanelli, F., Natale, G., Marino, G., Ghiglieri, V., & Calabresi, P. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105697 · Cited by 86
Dopamine Modulates Serotonin Innervation in the Drosophila Brain
Niens, J., Reh, F., Çoban, B., Cichewicz, K., Eckardt, J., Liu, Y.-T., Hirsh, J., & Riemensperger, T. D. (2017) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2017.00076 · Cited by 38
“The exact cause of LID is unknown, but dysfunctional 5-HT neuron plasticity triggered by the combined effects of DA neuron denervation and pharmacological DA replacement with L-DOPA have been implicated (Calabresi et al., 2000; Hirsch, 2000; Cenci and Lundblad, 2006; Cenci and Lindgren, 2007).”
Background
Metadata
- Authors
- Cenci, M. A., & Lundblad, M.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2006-07-26
- Volume
- 99
- Issue
- 2
- Pages
- 381-392
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1973564144
- Cited by
- 218
- References
- 12
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.